Role of AKR1C3 in renal injury and Glibenclamide (cas 10238-21-8) is anti-inflammatory in preeclamptic rats
-
Add time:07/25/2019 Source:sciencedirect.com
Proteinuria is a common adverse effect of renal injury in preeclampsia. To explore the effects of AKR1C3 in renal injury due to preeclampsia and to determine an optimal method to prevent proteinuria, Glibenclamide (cas 10238-21-8) treatment was used in unrestrained Wistar rats exposed to N-nitro-L-arginine methyl ester hydrochloride (L-NAME). Successful rat models for preeclampsia were confirmed based on mean arterial pressure, a 24-h protein urine test, and by observing the structure of the kidney by transmission electron microscopy (TEM). Forty Wistar rats were randomly divided into L-NAME-induced preeclampsia (pregnant and L-NAME), treatment (pregnant, L-NAME, and glybenclamide), non-pregnant (L-NAME), and control (pregnant and 0.9% saline) groups. Rats that were 19 days into their pregnancies were then euthanized and their kidneys were collected. After exposure to L-NAME, the mean arterial pressure increased by ~25 mmHg, which was largely prevented by the co-administration of glibenclamide. At 24 h, protein levels in the urine of the L-NAME-induced preeclampsia group were higher than those of the control and treatment groups. AKR1C3 was downregulated in the kidney and podocytes, whereas glibenclamide increased the expression of AKR1C3. The generation of reactive oxygen species (ROS) detected by ELISA was decreased by the glibenclamide co-administration. Compared with that in the L-NAME-induced preeclampsia group, the expression levels of AKR1C3 protein and mRNA significantly increased in the treatment group ([0.48 ± 0.09] vs.[1.05 ± 0.20];[0.05 ± 0.02] vs.[0.22 ± 0.06]; both P < 0.05]). Therefore, AKR1C3 expression was decreased in the kidneys of L-NAME-induced preeclampsia rats, and glibenclamide may be useful for the treatment of preeclampsia by regulating the generation of ROS and preventing proteinuria.
We also recommend Trading Suppliers and Manufacturers of Glibenclamide (cas 10238-21-8). Pls Click Website Link as below: cas 10238-21-8 suppliers
Prev:Electrochemical detection of gliclazide and Glibenclamide (cas 10238-21-8) on ZnIn2S4 nanoparticles-modified carbon ionic liquid electrode
Next:Neuroprotective potential of Glibenclamide (cas 10238-21-8) is mediated by antioxidant and anti-apoptotic pathways in intracerebral hemorrhage) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Characterization and evaluation of different mesoporous silica kinds as carriers for the development of effective oral dosage forms of Glibenclamide (cas 10238-21-8)07/31/2019
- Controlled release of Glibenclamide (cas 10238-21-8) from monolithic silica subdermal implants produced by the sol-gel process and its use for hyperglycaemia treatment in a murine model07/30/2019
- Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a Glibenclamide (cas 10238-21-8)-induced canine hypoglycaemia model07/29/2019
- Peceosomes for oral delivery of Glibenclamide (cas 10238-21-8): In vitro in situ correlation07/28/2019
- Low-voltage online stimulated microextraction of Glibenclamide (cas 10238-21-8) from whole blood07/27/2019
- Neuroprotective potential of Glibenclamide (cas 10238-21-8) is mediated by antioxidant and anti-apoptotic pathways in intracerebral hemorrhage07/26/2019
- Electrochemical detection of gliclazide and Glibenclamide (cas 10238-21-8) on ZnIn2S4 nanoparticles-modified carbon ionic liquid electrode07/24/2019
- Studying tautomerism in an important pharmaceutical Glibenclamide (cas 10238-21-8) confined in the thin nanometric layers07/23/2019